Nuvectis Pharma Inc (NVCT) returns
Nuvectis Pharma returns over 3 years
$1,000 invested in Nuvectis Pharma three years ago was worth $2,208 at the close on October 30, 2026, with dividends reinvested: an average return of 30.2% a year. The same $1,000 in the S&P 500 (SPY) became $1,885.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -12.5% | — | $875.00 | -0.9% |
| 3 months | -18.8% | — | $811.95 | +2.1% |
| Year to date | +144.8% | — | $2,448 | +11.7% |
| 1 year | +178.3% | — | $2,783 | +12.4% |
| 3 years | +120.8% | +30.2% | $2,208 | +88.5% |
Nuvectis Pharma return by calendar year
| Year | NVCT | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +144.8% | +11.7% | +133.1% |
| 2025 | +39.6% | +17.7% | +21.8% |
| 2024 | -35.1% | +24.9% | -60.0% |
| 2023 | +11.2% | +26.2% | -15.0% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also:
No forecast, no recommendation. This page describes Nuvectis Pharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.